Listen to The Lancet Gastroenterology & Hepatology

Simon Baunwall (Aarhus University Hospital) discusses the EarlyFMT trial, a randomized placebo-controlled trial of faecal microbiota transplantation for first or second Clostridioides difficile infection.

James Alexander (Imperial College London) discusses the latest findings from the VIP case-control study, which is investigating COVID-19 vaccine immune responses in immunosuppressed patients with inflammatory bowel disease.

Filip Knop (University of Copenhagen) discusses a trial of liraglutide versus colesevelam for the treatment of bile acid diarrhoea.

Edward Kim (Icahn School of Medicine at Mount Sinai) discusses the single-arm RASER study of radiation segmentectomy for patients with unresectable very early to early stage hepatocellular carcinoma.

Joep Ijspeert (Amsterdam University Medical Center) discusses a population-based study exploring the detection of proximal serrated polyps and interval post-colonoscopy colorectal cancer risk.

Elise Meima-van Praag (Amsterdam University Medical Centre) discusses the PISA-II trial, investigating short-term anti-TNF therapy with surgical closure versus anti-TNF therapy for perianal fistulas in Crohn's disease.

Juan Pablo Arab (Catholic University of Chile) discusses the current burden of NAFLD and the landscape of public health policies related to the disease in the Americas.

Sarah Blach (CDA Foundation) summarises the latest analysis of global hepatitis C virus epidemiology and cascade of care by the Polaris Observatory HCV Collaborators.

Sunil Solomon (Johns Hopkins University) discusses a study of a minimal monitoring approach for treating patients with hepatitis C virus infection.

Rupert Leong (University of Sydney) discusses a new double-blind, randomised, placebo-controlled trial of oral faecal microbiota transplantation for patients with active ulcerative colitis.

Swati Patel (University of Colorado Anschutz Medical Center) discusses the epidemiology, clinical features, biology, risk factors, and opportunities for prevention and detection of early-onset colorectal cancers.

Emilie Breekveldt (Erasmus Medical Center, Netherlands) discusses a new analysis of the faecal immunochemical testing-based colorectal screening programme in the Netherlands.

Wendy Spearman (University of Cape Town) discusses a Series on the emergence of non-alcoholic fatty liver disease in Sub-Saharan Africa and the challenges it presents.

Tim Vanuytsel (University of Leuven) discusses a new trial of spore-forming probiotics in functional dyspepsia.

Raymond Henderson (Queen’s University Belfast) discusses a new analysis of the economic burden of colorectal cancer in Europe.

Sigurður Ólafsson (Landspitali University Hospital) discusses newly published results from the nationwide programme to eliminate hepatitis C virus in Iceland.

Caroline Ovadia (King’s College London) discusses an individual participant data meta-analysis on the treatment of intrahepatic cholestasis of pregnancy with ursodeoxycholic acid.

Matthew Akiyama (Montefiore Medical Center and Albert Einstein College of Medicine, USA) discusses a Review on hepatitis C elimination among people incarcerated in prisons.

Monika Sarkar (University of California San Francisco, USA) discusses her Comment on reproductive health in women with chronic liver disease.

Ola Olén discusses the assesment of colorectal cancer risk in patients with Crohn's disease.

Dr Akbar Waljee discusses findings from a cohort study investigating the risk of cancer recurrence or a new primary cancer in patients with IBD, rheumatoid arthritis, or psoriasis who received anti-TNFα therapy.

Dr Kushala Abeysekara discusses research looking at the prevalence of non-alcoholic fatty liver disease in young adults in England.

Professor Alexander Ford discusses a meta analysis comparing different traditional treatments for irritable bowel syndrome.

Dr. Elisa Pose discusses the potential beneficial effects of statins on the treatment of patients with decompensated cirrhosis

Mohsen Naghavi describes the key findings from two new Global Burden of Disease studies investigating the global burden of pancreatic cancer and colorectal cancer.